AlphAIalphai — Financial news for AI agents
prnewswire.comJUL 291 min read$AMPH

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026

Amphastar Pharmaceuticals (NASDAQ: AMPH) said it will report second-quarter 2026 results for the period ended June 30, 2026 after the market closes on Aug. 6, 2026, and hold a conference call at 2:00 p.m. Pacific. A webcast replay will be posted on the company’s investor site within 24 hours.

Original reporting
prnewswire.com
Published Jul 29, 2026, 10:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 11:21 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026 — source image
Source · prnewswire.com
Decision brief

The 30-second read

$AMPHNeutralMed
01

Why it matters

The primary tradable element is the earnings event timing, which can affect implied volatility, options pricing, and short-term positioning. The press release contains no Q2 financials or forward guidance updates.

02

Market read

A routine earnings calendar update for AMPH, setting a clear catalyst date for after-hours volatility and call-driven repricing.

03

What to watch

Traders should focus on what management may emphasize on the call (guidance, BAQSIMI sales trajectory, pipeline timing), but those details are not included in this PR.

Relevance 4/10Novelty 3/10Timing: Ahead of the Aug 6, 2026 after-hours Q2 earnings release and 2:00 p.m. PT conference call.

Background

Amphastar is a biopharmaceutical company focused on technically challenging generics and proprietary injectable, inhalation, and intranasal products, plus API sales.

Company-level read

Ticker impact

$AMPHNeutralMedium confidence
Context

Amphastar (AMPH) will release Q2 2026 results after the close on Aug 6, 2026, and host a 2:00 p.m. PT call.

Expected impact

Likely elevated pre-earnings positioning and after-hours reaction risk; direction depends on Q2 results and any updated outlook.

Evidence & confidence

The article discloses only the timing of the earnings release and call, with no numbers, guidance, or new operational/regulatory developments.

Market effects

Sector

Biopharma/generic injectables names may see mild sector sentiment drift around earnings season, but no sector-wide new data is provided here.

Regional

No specific regional market impact beyond US small/mid-cap biotech earnings calendar effects.

Global

No global catalyst mentioned; impact is primarily company-specific around the earnings date.

Counterpoint

What could challenge this read

Because the release timing is already known to the market once scheduled, the incremental trading edge may be limited unless options positioning or consensus expectations are unusually misaligned.

Key entities

  • public_company
    Amphastar Pharmaceuticals, Inc.

    Announced Q2 2026 earnings release after the close on Aug 6, 2026, and a conference call at 2:00 p.m. Pacific.

Read at source← All news

Related articles

AUG 14
$AMPHMedAI 8/10

Amphastar (AMPH) Q2 2026 Earnings Call Transcript

Amphastar (AMPH) reported Q2 2026 net revenues of $183.9 million, up 5% from $174.4 million, and gross margin of 50.8% versus 49.6%. GAAP net income was $30.3 million ($0.67/share). Adjusted non-GAAP net income was $40.8 million ($0.91/share). IMS remediation tied to an FDA warning letter is expected to add $2 million to $3 million per quarter, while full-year sales growth guidance remains mid-single digit to high single digit.

fool.com6 min
AUG 6
$AMPHMedAI 8/10

Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Better

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q2 2026 results with revenue up 5.4% year on year to $183.9 million, exceeding Wall Street estimates by 2%, according to the company. Non-GAAP adjusted EPS was $0.91, up from $0.85, and 48.3% above consensus. The stock rose 4.5% to $20.70 after the release.

financialcontent.com4 min
AUG 6
$AMPHMed

Amphastar Pharmaceuticals, Inc. (AMPH): Results of Operations and Financial Condition

Amphastar Pharmaceuticals, Inc. (AMPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 amph-20260806xex99d1.htm EX-99.1 EXHIBIT 99.1 ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 ​ - Net revenues of $183.9 million for the three months ended June 30, 2026 ​ - GAAP net income of $30.3 million, or $0.67 per sh

SEC EDGAR 8-K7 min
JUL 9
$AMPHMedAI 8/10

A New Over-the-Counter Naloxone Nasal Spray Is Now Available at Pharmacies

The FDA approved Rextovy, a 4 mg naloxone hydrochloride nasal spray by Amphastar Pharmaceuticals, for over-the-counter sale on June 16, 2026. It joins Narcan (Emergent BioSolutions) and RiVive (Harm Reduction Therapeutics) as OTC naloxone options. The article cites overdose-death figures and says expanded access may affect retail pricing and availability.

medicaldaily.com5 min
JUN 10
$AMPHMed

Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth

Amphastar Pharmaceuticals said it is leaning more on proprietary drugs and biosimilars to drive growth, while keeping BAQSIMI and Primatene MIST as key branded products. In Phase 1, AMP-101 (intranasal epinephrine) and other early programs include AMP-105/109 oncology and AMP-107 for wet AMD. The company forecasts BAQSIMI peak sales of $250–$275M and peak incremental adjusted EPS of $2–$2.50, and Primatene MIST sales of $109M last year with high-single-digit growth. Amphastar reported $285M cash

finance.yahoo.com7 min
JUN 2
$AMPHMedAI 8/10

Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty

Piper Sandler cut its price target for Amphastar Pharmaceuticals (NASDAQ: AMPH) from $25 to $21 while keeping a Neutral rating, TheFly reported May 11. The firm cited limited visibility on when pipeline programs will produce meaningful results. Amphastar’s May 7 Q1 ended March 31, 2026 net revenues were $171.2M; GAAP EPS $0.14 and adjusted EPS $0.42.

finance.yahoo.com4 min